KMDA (Biotechnology) Stock Valuation & Fair Value Fairly valued
KMDA (Biotechnology) trades at a blended P/E of 17.6, about 14% below its historical normal valuation, with a forward growth estimate of 30.4% and a PEG of 0.58. Analysts' one-year estimates have been hit 36% of the time.
Valuation flags
- No notable valuation flags.
Frequently asked questions
Is KMDA overvalued?
At a blended P/E of 17.6 versus its historical normal P/E of 20.6, KMDA trades about 14% below its typical valuation, with a PEG of 0.58 on 30.4% forward growth. tickerseer currently rates it fairly valued.
What is KMDA's fair value and PEG?
KMDA trades at a blended P/E of 17.6 against a historical normal P/E of 20.6, a PEG of 0.58, and a forward growth estimate of 30.4%.
Has tickerseer's rating of KMDA changed?
tickerseer's rating has been fairly valued since 2026-08-07.
Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. Educational content, not investment advice.